Contrast enhanced cartilage imaging: Comparison of ionic and non-ionic contrast agents.
Our objective was to compare relaxation effects, dynamics and spatial distributions of ionic and non-ionic contrast agents in articular cartilage at concentrations typically used for direct MR arthrography at 1.5T. Dynamic MR-studies over 11h were performed in 15 bovine patella specimens. For each of the contrast agents gadopentetate dimeglumine, gadobenate dimeglumine, gadoteridol and mangafodipir trinatrium three patellae were placed in 2.5mmol/L contrast solution. Simultaneous measurements of T(1) and T(2) were performed every 30min using a high-spatial-resolution "MIX"-sequence. T(1), T(2) and DeltaR(1), DeltaR(2) profile plots across cartilage thickness were calculated to demonstrate the spatial and temporal distributions. The charge is one of the main factors which controls the amount of the contrast media diffusing into intact cartilage, but independent of the charge, the spatial distribution across cartilage thickness remains highly inhomogeneous even after 11h of diffusion. The absolute DeltaR(2)-effect in cartilage is at least as large as the DeltaR(1)-effect for all contrast agents. Maximum changes were 5-12s(-1) for DeltaR(1) and 8-15s(-1) for DeltaR(2). This study indicates that for morphologically intact cartilage only the amount of contrast agents within cartilage is determined by the charge but not the spatial distribution across cartilage thickness. In addition, DeltaR(2) can be considered for quantification of contrast agent concentrations, since it is of the same magnitude and less time consuming to measure than DeltaR(1).
Wiener
Edzard
E
Department of Radiology, Technical University Munich, Ismaninger Str. 22, D-81675 Munich, Germany. ewiener@roe.med.tu-muenchen.de
Woertler
Klaus
K
Weirich
Gregor
G
Rummeny
Ernst J
EJ
Settles
Marcus
M
D000818:Animals; D001175:Arthrography / Q000379:methods; D002358:Cartilage, Articular / Q000187:drug effects*; D002417:Cattle; D003287:Contrast Media / Q000493:pharmacokinetics*; D004492:Edetic Acid / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D005682:Gadolinium; D019786:Gadolinium DTPA / Q000493:pharmacokinetics; D006571:Heterocyclic Compounds / Q000008:administration & dosage; D007091:Image Processing, Computer-Assisted / Q000379:methods; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008536:Meglumine / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics; D017847:Patellar Ligament / Q000187:drug effects; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D012965:Sodium Chloride / Q000008:administration & dosage; D013997:Time Factors
D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C062402:gadoteridol; C064572:gadobenic acid; D012965:Sodium Chloride; D011732:Pyridoxal Phosphate; D008536:Meglumine; D004492:Edetic Acid; D005682:Gadolinium; D019786:Gadolinium DTPA; C060076:N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid